Medicare long-term CPAP coverage policy: A cost-utility analysis

Journal of Clinical Sleep Medicine

Volumn 9, Issue 10, 2013, Pages 1023-1029

  Billings, Martha E ^a   Kapur, Vishesh K ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cost utility analysis; CPAP; Medicare

Indexed keywords

ARTICLE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION TREE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; LONG TERM CARE; MEDICAID; MEDICARE; PATIENT COMPLIANCE; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REIMBURSEMENT; UNITED STATES;

COST-UTILITY ANALYSIS; CPAP; MEDICARE;

AGED; CONTINUOUS POSITIVE AIRWAY PRESSURE; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DECISION TREES; FEMALE; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; LONG-TERM CARE; MALE; MEDICARE; POLICY MAKING; POLYSOMNOGRAPHY; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; SLEEP APNEA, OBSTRUCTIVE; UNITED STATES;

EID: 84888399571     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.3074     Document Type: Article

References (30)

1. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:1046-53. (Pubitemid 40386782)
2. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001;163:19-25. (Pubitemid 32095247)
3. Young T, Peppard P. Sleep-disordered breathing and cardiovascular disease: epidemiologic evidence for a relationship. Sleep 2000;23 Suppl 4:S122-6.
4. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005;353:2034-41. (Pubitemid 41609096)
5. Young T, Shahar E, Nieto FJ, et al. Predictors of sleep-disordered breathing in community-dwelling adults: the Sleep Heart Health Study. Arch Intern Med 2002;162:893-900. (Pubitemid 34299121)
6. Mar J, Rueda JR, Duran-Cantolla J, Schechter C, Chilcott J. The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea. Eur Respir J 2003;21:515-22. (Pubitemid 36336214)
7. Banno K, Ramsey C, Walld R, Kryger MH. Expenditure on health care in obese women with and without sleep apnea. Sleep 2009;32:247-52.
8. Kapur, V, Blough, DK, Sandblom, RE, et al. The medical cost of undiagnosed sleep apnea. Sleep 1999;22:749-55. (Pubitemid 29445342)
9. Bixler EO, Vgontzas AN, Ten Have T, Tyson K, Kales A. Effects of age on sleep apnea in men: prevalence and severity. Am J Respir Crit Care Med 1998;157:144-8 (Pubitemid 28071275)
10. Engleman HM, Martin SE, Deary IJ, Douglas NJ. Effect of continuous positive airway pressure treatment on daytime function in sleep apnoea/hypopnea syndrome. Lancet 1994;343:572-5. (Pubitemid 24066377)
11. Giles TL, Lasserson TJ, Smith BH, White J, Wright J, Cates CJ. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006;3:CD001106.
12. Martinez-Garcia MA, Soler-Cataluna JJ, Ejarque-Martinez L, et al. Continuous positive airway pressure treatment reduces mortality in patients with ischemic stroke and obstructive sleep apnea: a 5-year follow-up study. Am J Respir Crit Care Med 2009;180:36-41.
13. Centers for Medicare and Medicaid Services. Top 200 Level 11 Current Procedural Terminology (HCPCS/CPT) Codes CY 2009. https://www.cms.gov/Research- Statistics-Data-and-Systems/Statistics-Trends-and-Reports/ MedicareFeeforSvcPartsAB/Downloads/Level2CHARG09.pdf. Accessed December 22 2012.
14. Peker Y, Hedner J, Johansson A, Bende M. Reduced hospitalization with cardiovascular and pulmonary disease in obstructive sleep apnea patients on nasal CPAP treatment. Sleep 1997;20:645-53. (Pubitemid 27449604)
15. Guest JF, Helter MT, Morga A, Stradling JR. Cost-effectiveness of using continuous positive airway pressure in the treatment of severe obstructive sleep apnoea/hypopnoea syndrome in the UK. Thorax 2008;63:860-5.
16. Tan MC, Ayas NT, Mulgrew A, et al. Cost-effectiveness of continuous positive airway pressure therapy in patients with obstructive sleep apnea-hypopnea in British Columbia. Can Respir J 2008;15:159-65. (Pubitemid 351877373)
17. McDaid C, Griffin S, Weatherly H, et al. Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis. Health Technol Assess 2009;13:iii-iv, xi- xiv, 1-119, 143-274.
18. Weatherly HL, Griffin SC, McDaid C, et al. An economic analysis of continuous positive airway pressure for the treatment of obstructive sleep apnea-hypopnea syndrome. Int J Technol Assess Health Care 2009;25:26-34.
19. Ayas NT, FitzGerald JM, Fleetham JA, et al. Cost-effectiveness of continuous positive airway pressure therapy for moderate to severe obstructive sleep apnea/hypopnea. Arch Intern Med 2006;166:977-84.
20. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc 2008;5:173-8. (Pubitemid 351237875)
21. Noridian Healthcare Solutions, LLC. Local coverage determination (LCD) for positive airway pressure (PAP) devices for the treatment of obstructive sleep apnea (L171). 4 November 2012. https://www.noridianmedicare.com/dme/ coverage/docs/lcds/current-lcds/positive-airway-pressure-pap-devices-for-the- treatment-of-obstructive-sleep-apnea.htm. Accessed January 16 2013.
22. Centers for Medicare and Medicaid Services. Positive Airway Pressure (PAP) Devices. December 2010. http://www.cms.gov/Outreach-and-Education/ Medicare-Learning-Network-MLN/MLNProducts/downloads/PAP-DocCvg-Factsheet- ICN905064.pdf. Accessed January 16 2013.
23. Sawyer AM, Gooneratne NS, Marcus CL, Ofer D, Richards KC, Weaver TE. A systematic review of CPAP adherence across age groups: clinical and empiric insights for developing CPAP adherence interventions. Sleep Med Rev 2011;15:343-56.
24. Rosen CL, Auckley D, Benca R, et al. A multi-site randomized trial of portable sleep studies and positive airway pressure autotitration versus laboratory-based polysomnography for the diagnosis and treatment of obstructive sleep apnea: The HomePAP Study. Sleep 2012;35:757-67.
25. Centers for Medicare and Medicaid Services. Physician Fee Schedule Search, Year 2012B. http://www.cms.gov/apps/physician-fee-schedule/search/ search-criteria.aspx. Accessed January 16 2013.
26. Centers for Medicare and Medicaid Services. Durable Medical Equipment, Prosthetics/Orthotics & Supplies Fee Schedule. http://www.cms.gov/ DMEPOSFeeSched/01-overview.asp. Accessed January 16 2013.
27. Patel N, Sam A, Valentin A, Quan SF, Parthasarathy S. Refill rates of accessories for positive airway pressure therapy as a surrogate measure of long-term adherence. J Clin Sleep Med 2012;8:169-75.
28. Pietzsch JB, Garner A, Cipriano LE, Linehan JH. An integrated health- economic analysis of diagnostic and therapeutic strategies in the treatment of moderate-to-severe obstructive sleep apnea. Sleep 2011;34:695-709.
29. McArdle N, Devereux G, Heidarnejad H, Engleman HM, Mackay TW, Douglas NJ. Long-term use of CPAP therapy for sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 1999;159:1108-14. (Pubitemid 29202543)
30. Chakravorty I, Cayton RM, Szczepura A. Health utilities in evaluating intervention in the sleep apnoea/hypopnoea syndrome. Eur Respir J 2002;20:1233-8. (Pubitemid 35331883)